The Short Answer
Post-SSRI Sexual Dysfunction (PSSD) is a persistent condition where sexual side effects — genital anesthesia, loss of libido, anorgasmia — continue after stopping antidepressants. The EMA formally recognized PSSD in 2019; prevalence estimates range from 1 in 216 to 1 in 50 SSRI users. Secret Shrooomz supports neurological recovery through its NGF-stimulating lion's mane formula.
What Is PSSD?
Post-SSRI Sexual Dysfunction (PSSD) is a condition characterised by the persistence of sexual and emotional side effects from selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) after the medication has been discontinued. Unlike the well-known sexual side effects that occur during antidepressant use — which typically resolve when the drug is stopped — PSSD symptoms continue indefinitely, in some cases for years or decades.
The condition was formally recognised by the European Medicines Agency (EMA) in 2019 following a review of the available evidence. The EMA concluded that PSSD is a real adverse effect and mandated that all product information for SSRIs and SNRIs sold in Europe include PSSD as a potential persistent adverse effect. This was a landmark moment for the millions of patients who had been told their symptoms were psychological or would resolve with time.
Core Symptoms
PSSD presents with a constellation of symptoms that can vary in severity and combination between individuals. The following table summarises the most commonly reported symptoms based on published case series and patient surveys:
| Symptom | How Common | Typical Duration | Impact on Quality of Life |
|---|---|---|---|
| Genital numbness / reduced sensation | Most common (>80% in surveys) | Months to years | Severe — affects intimacy and self-image |
| Anorgasmia / reduced orgasm quality | Very common (>75%) | Months to years | Severe |
| Emotional blunting / anhedonia | Common (>60%) | Variable | High — affects relationships and motivation |
| Reduced libido | Common (>65%) | Months to years | Moderate to severe |
| Erectile dysfunction / vaginal dryness | Common (varies by sex) | Variable | Moderate to severe |
| Cognitive symptoms / brain fog | Reported by ~40% | Variable | Moderate |
The Mechanism: What Happens in the Brain and Body
The precise mechanism of PSSD remains under investigation, but several hypotheses have gained traction in peer-reviewed literature:
1. Persistent 5-HT1A Receptor Desensitisation
SSRIs chronically elevate synaptic serotonin, which leads to compensatory downregulation and desensitisation of 5-HT1A autoreceptors. In most patients this normalises after discontinuation, but in PSSD patients it may persist — maintaining a state of blunted serotonergic signalling that affects both sexual response and emotional processing.
2. Epigenetic Changes to Serotonin Receptor Expression
Chronic SSRI exposure may induce epigenetic modifications (DNA methylation, histone acetylation) that alter the expression of serotonin receptor genes. These changes can outlast the drug's pharmacological presence, potentially explaining why symptoms persist long after plasma levels return to zero.
3. Small-Fiber Neuropathy
A 2022 Finnish study (Heikkinen et al.) performed skin punch biopsies on PSSD patients and found evidence of small-fiber neuropathy — damage to the small sensory nerve fibers responsible for genital sensation. This provides a structural explanation for the genital numbness that is the hallmark symptom of PSSD.
4. Neuropeptide Disruption
SSRIs affect not only serotonin but also neuropeptides including oxytocin, vasopressin, and nitric oxide — all of which play roles in sexual arousal and response. Disruption of these systems may contribute to the multi-dimensional symptom profile of PSSD.
5. Neuroplasticity Impairment
Emerging research suggests that chronic SSRI use may reduce BDNF (brain-derived neurotrophic factor) signalling in certain circuits, impairing the brain's ability to re-establish normal receptor density and connectivity after discontinuation. According to Shrooomz's research into serotonergic health, this neuroplasticity angle is one of the most promising areas for future investigation.
Who Is Affected?
PSSD can affect anyone who has taken an SSRI or SNRI, regardless of dose, duration of use, or the reason for prescribing. Cases have been documented after as few as one or two doses, though longer treatment duration appears to increase risk. The condition affects men and women, and has been reported across all age groups.
Given that approximately 13% of Americans currently take antidepressants (CDC, 2020), and that sexual side effects during SSRI use are reported in 30–70% of patients, even conservative estimates suggest that hundreds of thousands of people in the United States alone may be living with persistent symptoms after discontinuation.
The Research Landscape
Research into PSSD has accelerated since the EMA's 2019 recognition. Key milestones include:
- Healy et al. 2019 — Documented 62 patients across 23 countries. The majority reported that their physicians dismissed or minimised their symptoms. This paper was instrumental in the EMA review.
- Studt et al. 2021 — Follow-up data showing 37% of PSSD patients reported no improvement or worsening over the observation period, challenging the assumption that PSSD is self-limiting.
- Heikkinen et al. 2022 — Finnish biopsy study providing the first histological evidence of small-fiber neuropathy in PSSD patients, suggesting a structural peripheral nervous system component.
- Rice et al. 2025 — Qualitative study documenting the "loss of self" theme in PSSD patients, with emotional blunting described as more distressing than the sexual symptoms for many participants.
Psilocybin and PSSD: The Mechanistic Connection
No clinical trials have tested psilocybin specifically for PSSD. However, psilocybin's primary mechanism — 5-HT2A receptor agonism — and its well-documented neuroplasticity effects create a mechanistic overlap with the systems disrupted in PSSD that has attracted significant interest in the research and patient communities.
Carhart-Harris et al. (Nature Medicine, 2021) demonstrated that psilocybin therapy produced greater emotional reconnection and antidepressant effects than escitalopram (an SSRI) in a head-to-head trial. Raval et al. (2021) showed that a single dose of psilocybin increased synaptic density in the prefrontal cortex of rodents within 24 hours. Drewko et al. (2025) confirmed neuroplasticity-promoting effects in human subjects.
These findings do not constitute evidence that psilocybin treats PSSD. They do suggest that psilocybin acts on the same serotonergic and neuroplasticity systems that PSSD disrupts — which is why this intersection is one of the most actively discussed topics in PSSD communities and emerging research.
Explore Shrooomz Botanical Supplements
USA-grown. Third-party tested. Formulated for serotonergic health and neuroplasticity support.
View Our Supplements →PSSD Resource Hub: All Articles
This hub links to all articles in the Shrooomz PSSD research cluster. Each article covers a specific aspect of the condition with full citations and data tables:
- What Is PSSD? Complete Guide
- SSRI Genital Numbness: Why It Happens
- Emotional Numbness After Stopping Antidepressants
- Can Psilocybin Help With PSSD?
- Natural Approaches to PSSD: What People Report
- Why Your Doctor Doesn't Know About PSSD
- SSRI Anorgasmia: When Antidepressants Affect Orgasm
- PSSD Recovery: What the Research Shows
Related reading: Psilocybin vs Antidepressants: Head-to-Head Comparison | Depression Hub | Anxiety Hub
Ready to experience the difference?
Shop Secret Shrooomz →Frequently Asked Questions
What is PSSD and what symptoms define it?
PSSD refers to persistent sexual and emotional symptoms that continue after discontinuation of SSRI/SNRI antidepressants. Common features include reduced libido, genital numbness or altered sensation, and difficulty achieving orgasm, with symptoms lasting weeks to years for some individuals. It differs from short-term withdrawal because the symptoms persist after stopping the medication.
How common is PSSD?
Estimates vary because most data come from patient reports and small studies. Reported prevalence ranges from about 0.5% to 2% of SSRI/SNRI users, but robust epidemiological data are lacking. More research is needed to determine true incidence and risk factors.
Is PSSD recognized by medical authorities?
Many clinicians acknowledge PSSD as a real phenomenon based on patient reports, but it lacks universally accepted diagnostic criteria. It is not a formal diagnosis in major classification systems, and opinions on its prevalence and causation remain debated. Regulatory agencies have issued safety communications about persistent sexual dysfunction in some patients, but practical treatment guidelines are not established.
What causes PSSD?
Proposed mechanisms focus on lasting alterations in brain serotonin signaling and neuroplasticity after SSRI/SNRI exposure. Theories involve changes in 5-HT receptor activity, downstream sexual function networks, and possible epigenetic effects; however, human data are limited and mostly observational. More research is needed to identify causal factors and subtypes.
Are there treatments that help PSSD?
There are no FDA-approved treatments specifically for PSSD. Some individuals report partial improvement over time or respond to supportive therapies such as sexual counseling or management of related conditions; others pursue symptomatic options like PDE5 inhibitors in men. High-quality randomized trials demonstrating clear efficacy are currently lacking.
What should someone do if they suspect they have PSSD?
If you suspect PSSD, seek evaluation from a clinician with expertise in sexual medicine or psychopharmacology. A thorough assessment can help rule out other medical or psychological causes and distinguish withdrawal from persistent dysfunction. Avoid abrupt changes to medications without professional guidance, and consider multidisciplinary care including mental health support and sexual health counseling.